Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV drug sensitivity assays

Executive Summary

FDA's Blood Products Advisory Committee will meet Sept. 17 to discuss reclassification of HIV drug sensitivity assays. On Sept. 16, the committee will receive an update on a guidance on precautionary measures to reduce possible transmission of Creutzfeldt Jakob Disease and new variants by blood products. The committee will also hear presentations on antigen antibody testing for malaria and strategies for increasing the blood supply, and discuss nucleic acid testing of blood donors for human paravirus B-19. The meeting will begin at 8 a.m. at the Ramada Inn in Bethesda, Md
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel